BACKGROUND: HMG-CoA reductase inhibitors (statins) reduce the risk of venous thromboembolism (VTE) in healthy people. Statins reduce levels of inflammation biomarkers; however, the mechanism for the reduction in VTE risk is unknown. AIM: In a large cohort of healthy people, we studied associations of statin use with plasma hemostatic factors related to VTE risk. METHODS: Cross-sectional analyses were performed in the Multi-Ethnic Study of Atherosclerosis (MESA), a cohort study of 6814 healthy men and women aged 45-84 years, free of clinical cardiovascular disease at baseline; 1001 were using statins at baseline. Twenty-three warfarin users were excluded. Age, race and sex-adjusted mean hemostatic factor levels were compared between statin users and non-users, and multivariable linear regression models were used to assess associations of statin use with hemostatic factors, adjusted for age, race/ethnicity, education, income, aspirin use, hormone replacement therapy (in women), and major cardiovascular risk factors. RESULTS: Participants using statins had lower adjusted levels of D-dimer (- 9%), C-reactive protein (- 21%) and factor VIII (- 3%) than non-users (P < 0.05). Homocysteine and von Willebrand factor levels were non-significantly lower with statin use. Higher fibrinogen (2%) and plasminogen activator inhibitor-1 (22%) levels were observed among statin users than among non-users (P < 0.05). Further adjustment for LDL and triglyceride levels did not attenuate the observed differences in these factors with statin use. CONCLUSIONS: Findings of lower D-dimer, FVIII and C-reactive protein levels with statin use suggest hypotheses for mechanisms whereby statins might lower VTE risk. A prospective study or clinical trial linking these biochemical differences to VTE outcomes in statin users and non-users is warranted.
BACKGROUND: HMG-CoA reductase inhibitors (statins) reduce the risk of venous thromboembolism (VTE) in healthy people. Statins reduce levels of inflammation biomarkers; however, the mechanism for the reduction in VTE risk is unknown. AIM: In a large cohort of healthy people, we studied associations of statin use with plasma hemostatic factors related to VTE risk. METHODS: Cross-sectional analyses were performed in the Multi-Ethnic Study of Atherosclerosis (MESA), a cohort study of 6814 healthy men and women aged 45-84 years, free of clinical cardiovascular disease at baseline; 1001 were using statins at baseline. Twenty-three warfarin users were excluded. Age, race and sex-adjusted mean hemostatic factor levels were compared between statin users and non-users, and multivariable linear regression models were used to assess associations of statin use with hemostatic factors, adjusted for age, race/ethnicity, education, income, aspirin use, hormone replacement therapy (in women), and major cardiovascular risk factors. RESULTS: Participants using statins had lower adjusted levels of D-dimer (- 9%), C-reactive protein (- 21%) and factor VIII (- 3%) than non-users (P < 0.05). Homocysteine and von Willebrand factor levels were non-significantly lower with statin use. Higher fibrinogen (2%) and plasminogen activator inhibitor-1 (22%) levels were observed among statin users than among non-users (P < 0.05). Further adjustment for LDL and triglyceride levels did not attenuate the observed differences in these factors with statin use. CONCLUSIONS: Findings of lower D-dimer, FVIII and C-reactive protein levels with statin use suggest hypotheses for mechanisms whereby statins might lower VTE risk. A prospective study or clinical trial linking these biochemical differences to VTE outcomes in statin users and non-users is warranted.
Authors: M Cushman; C Legault; E Barrett-Connor; M L Stefanick; C Kessler; H L Judd; P A Sakkinen; R P Tracy Journal: Circulation Date: 1999-08-17 Impact factor: 29.690
Authors: Vijay Nambi; Lloyd Chambless; Aaron R Folsom; Max He; Yijuan Hu; Tom Mosley; Kelly Volcik; Eric Boerwinkle; Christie M Ballantyne Journal: J Am Coll Cardiol Date: 2010-04-13 Impact factor: 24.094
Authors: David M Herrington; Eric Vittinghoff; Feng Lin; Josephine Fong; Fran Harris; Donald Hunninghake; Vera Bittner; Helmut G Schrott; Roger S Blumenthal; Robert Levy Journal: Circulation Date: 2002-06-25 Impact factor: 29.690
Authors: Nancy Swords Jenny; Nels C Olson; Matthew A Allison; Dena E Rifkin; Lori B Daniels; Ian H de Boer; Christina L Wassel; Russell P Tracy Journal: Glob Heart Date: 2016-09
Authors: Aneel A Ashrani; Michel K Barsoum; Daniel J Crusan; Tanya M Petterson; Kent R Bailey; John A Heit Journal: Thromb Res Date: 2015-04-11 Impact factor: 3.944
Authors: Neil A Zakai; Nels C Olson; Suzanne E Judd; Dawn O Kleindorfer; Brett M Kissela; George Howard; Mary Cushman Journal: Thromb Haemost Date: 2017-07-06 Impact factor: 5.249
Authors: K L Cheung; N A Zakai; P W Callas; G Howard; B K Mahmoodi; C A Peralta; S E Judd; M Kurella Tamura; M Cushman Journal: J Thromb Haemost Date: 2018-08-09 Impact factor: 5.824
Authors: N C Olson; M Cushman; P L Lutsey; L A McClure; S Judd; R P Tracy; A R Folsom; N A Zakai Journal: J Thromb Haemost Date: 2014-10-31 Impact factor: 5.824
Authors: Aaron R Folsom; Alvaro Alonso; Kristen M George; Nicholas S Roetker; Weihong Tang; Mary Cushman Journal: Thromb Res Date: 2015-08-28 Impact factor: 3.944